Phreesia, Inc. (PHR) P/E Ratio History
ExpensiveTrading at 296.0x vs 5Y avg 164.3x · 75th percentile · Material premium to history · Data 2026–2027
Loading P/E history...
P/E Ratio Analysis
As of July 7, 2026, Phreesia, Inc. (PHR) trades at a price-to-earnings ratio of 296.0x, with a stock price of $11.10 and trailing twelve-month earnings per share of $0.15.
The current P/E is 80% above its 5-year average of 164.3x. Over the past five years, PHR's P/E has ranged from a low of 55.7x to a high of 387.0x, placing the current valuation at the 75th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.5x, PHR trades at a 1159% premium to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 199.4x.
Relative to the broader market, PHR commands a significant premium over the S&P 500 median P/E of 25.6x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our PHR DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
PHR Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
PHR P/E vs Peers
Patient Engagement, Intake and Payments peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $4B | 23.3 | 0.45Best | -12% | |
| $1B | 36.1 | - | +104% | |
| $31B | 35.3 | 1.94 | +26% | |
| $2B | 6.6Lowest | 0.64 | +817%Best | |
| $2B | 47.6 | 7.10 | +14% | |
| $4B | 549.5 | - | +113% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
PHR Historical P/E Data (2026–2027)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2027 Q1 | - | $9.21 | $0.15 | 61.9x | -62% |
| FY2026 Q4 | Jan 31 2026 | $13.43 | $0.03 | 387.0x | +136% |
| FY2026 Q2 | - | $26.96 | $0.48 | 55.7x | -66% |
| FY2026 Q1 | Apr 30 2025 | $24.96 | $0.16 | 152.6x | -7% |
Average P/E for displayed period: 164.3x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10-year return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
PHR — Frequently Asked Questions
Quick answers to the most common questions about buying PHR stock.
What is PHR's P/E ratio?
Phreesia, Inc. (PHR) trailing twelve-month P/E ratio is 296.0x, based on TTM diluted EPS of $0.15. The 5-year average P/E is 164.3x and the historical range spans 55.7x to 387.0x.
Is PHR stock overvalued or undervalued?
PHR trades at 296.0x P/E, above its 5-year average of 164.3x. The 75th percentile ranking within the 55.7x–387.0x historical range indicates a premium to historical valuation.
Is PHR stock expensive?
Yes, PHR is expensive relative to its own history. The current P/E of 296.0x is above the 5-year average of 164.3x and also above the Healthcare sector median of 23.5x. The stock sits at the 75th percentile of its 5-year valuation range.
What is PHR's historical P/E range?
Over the past 5 years, PHR's P/E ratio has ranged from 55.7x to 387.0x, with a median of 152.6x and an average of 164.3x. The current P/E of 296.0x places the stock at the 75th percentile of this range. Full historical data spans 2026–2027.
How does PHR's P/E compare to the S&P 500?
PHR trades at 296.0x P/E versus the S&P 500 median of 25.6x. The 1056% premium to the market typically reflects higher expected earnings growth or quality.
How does PHR's valuation compare to Healthcare peers?
Phreesia, Inc. P/E of 296.0x compares to the Healthcare sector median of 23.5x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is PHR's PEG ratio?
PHR PEG ratio is N/A, based on a P/E of 296.0x and EPS growth of 103.7%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is PHR's earnings yield?
PHR earnings yield is 0.34%, the inverse of its 296.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.